Acute Myeloid Leukemia Research
Research Guide

The World Health Organization classification of myeloid neoplasms and acute leukemia was revised in 2016 by Arber et al. to include unique biomarkers identified since 2008. The 2009 revision by Vardiman et al. updated the 4th edition with rationale for changes in categorization. These systems provide standards for recording cases in clinical trials.

Bonnet and Dick (1997) demonstrated that human AML is organized as a hierarchy originating from a primitive hematopoietic cell. Lapidot et al. (1994) identified a cell initiating human AML after transplantation into SCID mice. These findings establish the leukemia stem cell model.

Döhner et al. (2016) published 2017 ELN recommendations for diagnosis and management of AML in adults, building on the 2010 edition with advances in genetic discoveries. These guidelines have broad acceptance among physicians treating AML patients. They emphasize risk-adapted therapy.

Ley (2013) mapped genomic and epigenomic landscapes of adult de novo AML, identifying at least one potential driver mutation in nearly all samples. A complex interplay of genetic events contributes to pathogenesis in individual patients. The study's databases support further AML investigations.

Bennett et al. (1976) proposed the French-American-British (FAB) classification for acute leukemias to standardize nomenclature and distribution in clinical trials. It serves as a reference for newly developed cell-surface markers. This system facilitated early comparative studies.

Recent preprints like 'The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes' (2025) use single-cell RNA sequencing on 120 AMLs to reveal cellular heterogeneity. Tools such as Tazi et al.'s unified classification model at aml-risk-model.com integrate risk-stratification. News highlights ASH 2025 presentations on ECOG-ACRIN studies.